- Previous Close
4.3000 - Open
4.4800 - Bid 4.3500 x --
- Ask 4.4000 x --
- Day's Range
4.2000 - 4.4800 - 52 Week Range
1.6100 - 5.0200 - Volume
216,776 - Avg. Volume
155,265 - Market Cap (intraday)
772.93M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company's products under development include Alpha1H for the treatment of bladder cancer and brain tumors; and BAMLET for the treatment of colon and oral cancer. The company was formerly known as Hamlet Pharma AB (publ) and changed its name to Hamlet BioPharma AB (publ) in August 2023. Hamlet BioPharma AB (publ) was incorporated in 1999 and is based in Lund, Sweden. Hamlet BioPharma AB (publ) is a subsidiary of Linnane Pharma AB.
www.hamletpharma.comRecent News: HAMLET-B.ST
View MorePerformance Overview: HAMLET-B.ST
Trailing total returns as of 2/28/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HAMLET-B.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HAMLET-B.ST
View MoreValuation Measures
Market Cap
772.93M
Enterprise Value
742.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
11.65
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-47.57%
Return on Equity (ttm)
-83.85%
Revenue (ttm)
-38.48k
Net Income Avi to Common (ttm)
-48.49M
Diluted EPS (ttm)
-0.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
30.39M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-22.04M